Oracle stock price jumps 3% as ORCL outpaces tech in morning trade
26 January 2026
1 min read

Oracle stock price jumps 3% as ORCL outpaces tech in morning trade

New York, Jan 26, 2026, 10:49 EST — Regular session

  • Oracle shares climbed roughly 3.3%, outpacing the broader tech sector’s gains.
  • A fresh life-sciences client has started using the company’s Argus safety software, the firm revealed.
  • Traders are focused on the Fed’s rate decision set for Jan. 28 and Oracle’s earnings due in mid-March.

Oracle shares climbed 3.3% to $182.98 on Monday, beating the tech sector’s 0.7% increase and the Nasdaq 100’s roughly 0.5% gain. Microsoft and Amazon also pushed higher.

This shift is significant as Oracle has weighed heavily in the debate over how quickly heavy AI infrastructure spending translates into revenue. Back in December, the stock dropped after the company’s forecasts came up short and it warned of much higher capital expenditures. 1

Investors are gearing up for the Federal Reserve meeting this week, which could shift rate expectations and impact risk appetite in mega-cap tech. The Fed convenes January 27-28, with its decision set for Wednesday. 2

Oracle highlighted new customer interest in a specialized area of its software lineup. Voisin Consulting Life Sciences, a contract research organization, selected Oracle Argus for pharmacovigilance tasks, the company announced. Seema Verma, Oracle Health and Life Sciences executive vice president, described it as a “dependable, advanced safety solution.” 3

This announcement veers away from the cloud-infrastructure story that’s fueled Oracle’s ups and downs. Still, it bolsters management’s argument that the company can push vertical software alongside its platform services.

Oracle has pointed to contracted cloud commitments to signal demand strength. In its fiscal second-quarter results released in December, the company reported $523 billion in remaining performance obligations—a metric showing contracted revenue still to be recognized—and noted a 68% jump in cloud infrastructure revenue. 4

The sticking point remains how those commitments will actually be fulfilled. Oracle’s expansion has drawn sharp questions about financing and follow-through, especially after bondholders sued over disclosures related to debt for AI infrastructure. 5

Another risk: changes in rates or credit conditions might hit highly capital-intensive trade setups first, even if the core demand remains steady.

Traders are now focused on whether Monday’s shift will stick after the Fed’s Jan. 28 decision, a key date that could shake up rate-sensitive tech stocks.

Oracle plans to release its fiscal third-quarter update in mid-March, according to the company. 6

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
Northern Dynasty (NAK) stock jumps 16% as gold hits $5,100 and Pebble case deadline nears
Previous Story

Northern Dynasty (NAK) stock jumps 16% as gold hits $5,100 and Pebble case deadline nears

Palantir stock price today: PLTR slips as Fed week starts and Feb. 2 earnings loom
Next Story

Palantir stock price today: PLTR slips as Fed week starts and Feb. 2 earnings loom

Go toTop